The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome
Open accessAbstract
BACKGROUND: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPL) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β2GPI antibodies was not reported. OBJECTIVE: To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β2GPI antibodies. METHODS: ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events. RESULTS: Anti-β2GPI IgG/IgA/IgM were the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM were detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β2GPI nor with thrombosis. CONCLUSIONS: aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of thrombotic complications in critically ill ICU patients with COVID-19
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.013 · Cited by 5,028
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179
Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., Kucher, N., Studt, J.-D., Sacco, C., Bertuzzi, A., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.024 · Cited by 2,054
Diagnosis and management of the antiphospholipid syndrome
Garcia, D., & Erkan, D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705454 · Cited by 819 · cited 4×
“Accordingly, anticoagulant prophylaxis or therapies affecting cell signaling involved in inflammatory and coagulation responses could be justified before a confirmatory assay (3, 37).”
BackgroundMethodInfluentialCharacteristics of ischaemic stroke associated with COVID-19
Beyrouti, R., Adams, M. E., Benjamin, L., Cohen, H., Farmer, S. F., Goh, Y. Y., Humphries, F., Jäger, H. R., Losseff, N. A., Perry, R. J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323586 · Cited by 711
Martinuzzo, M. E., Barrera, L. H., D 'Adamo, M. A., Otaso, J. C., Gimenez, M. I., & Oyhamburu, J. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12138 · Cited by 91 · cited 2×
“However, it is important to point out that LA is a very sensitive assay and its outcome can be influenced by several factors, most notably heparin administration (8) and a profound inflammatory state characterized by high levels of C reactive protein (CRP) (9, 10).”
BackgroundCattini, M. G., Bison, E., Pontara, E., Cheng, C., Denas, G., & Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14765 · Cited by 68
Cited by
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
Zuo, Y., Estes, S. K., Ali, R. A., Gandhi, A. A., Yalavarthi, S., Shi, H., Sule, G., Gockman, K., Madison, J. A., Zuo, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3876 · Cited by 660
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M. S., & Kanneganti, T.-D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 618
The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19
Schultheiß, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Henkes, S.-S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100663 · Cited by 431
COVID-19 and Cardiovascular Disease: From Bench to Bedside
Chung, M. K., Zidar, D. A., Bristow, M. R., Cameron, S. J., Chan, T., Harding, C. V., Kwon, D. H., Singh, T., Tilton, J. C., Tsai, E. J., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.317997 · Cited by 373
COVID-19 vasculitis and novel vasculitis mimics
McGonagle, D., Bridgewood, C., Ramanan, A. V., Meaney, J. F. M., & Watad, A. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30420-3 · Cited by 192
Metadata
- Authors
- Borghi, M. O., Beltagy, A., Garrafa, E., Curreli, D., Cecchini, G., Bodio, C., Grossi, C., Blengino, S., Tincani, A., Franceschini, F., Andreoli, L., Lazzaroni, M. G., Piantoni, S., Masneri, S., Crisafulli, F., Brugnoni, D., Muiesan, M. L., Salvetti, M., Parati, G., Torresani, E., Mahler, M., Heilbron, F., Pregnolato, F., Pengo, M., Tedesco, F., Pozzi, N., & Meroni, P. L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-15
- Volume
- 11
- Pages
- 584241-584241
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3093252727
- Cited by
- 193
- References
- 7
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. https://app.cochat.ai/papers/10.3389/fimmu.2020.584241
- The paper
- Borghi, M. O., Beltagy, A., Garrafa, E., Curreli, D., Cecchini, G., Bodio, C., Grossi, C., Blengino, S., Tincani, A., Franceschini, F., Andreoli, L., Lazzaroni, M. G., Piantoni, S., Masneri, S., Crisafulli, F., Brugnoni, D., Muiesan, M. L., Salvetti, M., Parati, G., . . . Meroni, P. L. (2020). Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.584241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.